Concepedia

Initial testing of topotecan by the pediatric preclinical testing program

Hernán Carol, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, Amy Watkins,

Pediatric Blood & Cancer · 2009 · 42 citations · 44 references

DOIFull text

Open access

Abstract

Topotecan demonstrated broad activity in vitro and in vivo against both the solid tumor and ALL panels, with significant tumor growth delay generated in all the panels. These results further demonstrate the validity of the PPTP panel for preclinical testing of new drugs.

References

44

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Y H Hsiang, Robert Hertzberg, Sidney M. Hecht et al. · Journal of Biological Chemistry · 1985 · 2.3K citations · Full text

, , +12

The pediatric preclinical testing program: Description of models and early testing results

Peter J. Houghton, Christopher L. Morton, Chandra L. Tucker et al. · Pediatric Blood & Cancer · 2006 · 482 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

Andrea Ardizzoni, H. Hansen, P Dombernowsky et al. · Journal of Clinical Oncology · 1997 · 479 citations

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

Peter J. Houghton, Pamela J. Cheshire, James D. Hallman et al. · Cancer Chemotherapy and Pharmacology · 1995 · 406 citations

, , +9

Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study

Robert L. Saylors, Kimo C. Stine, Jim Sullivan et al. · Journal of Clinical Oncology · 2001 · 314 citations